KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Biolife Solutions (BLFS) Long-Term Debt Issuances (2016 - 2022)

Biolife Solutions (BLFS) has disclosed Long-Term Debt Issuances for 9 consecutive years, with $20.0 million as the latest value for Q3 2022.

Quarterly Long-Term Debt Issuances rose 1660.06% to $20.0 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $20.0 million for FY2022, 1190.32% up from the prior year.
Long-Term Debt Issuances for Q3 2022 was $20.0 million at Biolife Solutions, up from $1.5 million in the prior quarter.
The five-year high for Long-Term Debt Issuances was $20.0 million in Q3 2022, with the low at -$2.2 million in Q4 2020.
Average Long-Term Debt Issuances over 3 years is $3.1 million, with a median of $1.1 million recorded in 2021.
The sharpest move saw Long-Term Debt Issuances tumbled 89.43% in 2021, then surged 1660.06% in 2022.
Over 3 years, Long-Term Debt Issuances stood at -$2.2 million in 2020, then surged by 171.26% to $1.5 million in 2021, then soared by 1190.32% to $20.0 million in 2022.
According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at $20.0 million, $1.5 million, and -$1.3 million for Q3 2022, Q4 2021, and Q3 2021 respectively.